Pharmaceutical

China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG

China’s NMPA has granted approval for Zai Lab and argenx's efgartigimod SC for the treatment of generalised myasthenia gravis (gMG).

Jul 18, 2024 - 04:00
China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG
China’s NMPA has granted approval for Zai Lab and argenx's efgartigimod SC for the treatment of generalised myasthenia gravis (gMG).
Read the original article

Tags:

Previous Article

Scorpion Therapeutics secures $150m for oncology pipeline

Next Article

FDA issues CRL to Orexo’s NDA for opioid overdose medication

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

In pigs, researchers show ultrasound could be used for 3D printing inside the body

In pigs, researchers show ultrasound could be used for ...

Dec 7, 2023

STAT+: Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

STAT+: Bipartisan group of lawmakers warns of a rising ...

Feb 17, 2024

Eli Lilly inaugurates R&D facility in Boston, US

Eli Lilly inaugurates R&D facility in Boston, US

Aug 15, 2024